<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="44383">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02528500</url>
  </required_header>
  <id_info>
    <org_study_id>AAA 13-02</org_study_id>
    <nct_id>NCT02528500</nct_id>
  </id_info>
  <brief_title>GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Type IV Thoracoabdominal Aortic Aneurysms Involving the Visceral Branch Vessels</brief_title>
  <acronym>TAMBE</acronym>
  <official_title>Early Feasibility Assessment of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Type IV Thoracoabdominal Aortic Aneurysms Involving the Visceral Branch Vessels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>W.L.Gore &amp; Associates</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>W.L.Gore &amp; Associates</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the initial feasibility of the GORE® EXCLUDER® Thoracoabdominal
      Branch Endoprosthesis (TAMBE Device) in the treatment of Aortic Aneurysms Involving the
      Visceral Branch Vessels.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of the following procedural safety events: Death, Stroke, Myocardial Infarction, Bowel Ischemia, Paraplegia, Respiratory Failure, Renal Failure, Procedural Blood Loss ≥1000 mL</measure>
    <time_frame>Absence of procedural safety events through 30 days post procedure</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Thoracoabdominal Aortic Aneurysm</condition>
  <arm_group>
    <arm_group_label>GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis</intervention_name>
    <description>Non-randomized, multicenter study designed to assess the initial feasibility of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)</description>
    <arm_group_label>GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aortic aneurysm involving the visceral vessels requiring treatment

          2. Adequate access for TAMBE Device components

          3. Appropriate aortic anatomy to receive the TAMBE Device

          4. Age ≥ 18 years at the time of informed consent signature

          5. Male or infertile female

          6. The patient is considered high risk for open repair as deemed by the treating
             physician

          7. Capable of complying with protocol requirements, including follow-up

          8. An Informed Consent Form signed by Subject or legal representative Note: Additional
             Inclusion Criteria may apply

        Exclusion Criteria:

          1. Prior aortic surgery

          2. Ruptured or leaking aortic aneurysm

          3. Aneurysmal dilatation due to chronic aortic dissection

          4. Infected aorta

          5. Mycotic aneurysm

          6. Life expectancy &lt;2 years

          7. Myocardial infarction or stroke within 6 weeks of treatment

          8. Systemic infection which may increase risk of endovascular graft infection

          9. Degenerative connective tissue disease, e.g. Marfan's or Ehler-Danlos Syndrome

         10. Participation in another drug or medical device study within 1 year of study
             enrollment

         11. History of drug abuse, e.g. cocaine or amphetamine or alcohol, within 1 year of
             treatment

         12. Tortuous or stenotic iliac and / or femoral arteries and the inability to use a
             conduit for vascular access

         13. Known sensitivities or allergies to the device materials

         14. Previous instance of Heparin Induced Thrombocytopenia type 2 (HIT-2) or known
             hypersensitivity to heparin

         15. Patient has body habitus or other medical condition which prevents adequate
             fluoroscopic and CT visualization of the aorta

         16. Renal Insufficiency Note: Additional Exclusion Criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Makaroun, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UPMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 18, 2016</lastchanged_date>
  <firstreceived_date>August 17, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Thoracic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
